KCT0004933撤回未知
A phase II clinical Trial for evaluating efficacy and safety of PDR001(Spartalizumab) in concurrent plus consolidation versus consolidation only in addition to standard chemotherapy in unresectable stage III NSCLC patients(PASTURE)
试验速览
- 阶段
- 未知
- 状态
- 撤回
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •? Patients with cytologically or histologically proven, locally advanced, treatment-naïve, unresectable, both squamous and non-squamous stage III NSCLC* (According to AJCC TNM staging 8th edition, IIIB and IIIC diseases are eligible; Inoperable stage IIIA disease without any exclusion criteria is also eligible)
- •? Patients with targetable mutations such as EGFR, ALK and ROS1 are also eligible.
- •However, genetic mutation testing is not required before registration
- •? Measurable disease based on RECIST 1.1 as determined by the site.
- •? Men and women = 20 years of age
- •? A performance status of 0 - 1 on the Eastern Cooperative Oncology Group (ECOG) performance Status
- •? Adequate hematologic, renal, and hepatic function as follows:
- •Absolute Neutrophil Count (ANC), > 1,000/mm3
- •Platelets > 100,000/mm3
- •Hemoglobin > 9.0 g/dL
- •Serum creatinine < 1.5 × upper normal limit (ULN) OR creatinine clearance > 45 mL/min/1.73m2
- •AST and/or ALT < 2.5 × the ULN
- •Bilirubin < 1.5 × the ULN
- •? 12-Lead electrocardiogram (ECG) shows QTc interval =470 msec and without history of Torsades de Pointes or other symptomatic QTc abnormality
- •? Written (signed) Informed Consent to participate in the study
排除标准
- •? Prior exposure to any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associate antigen-4 (CTLA-4) antibody
- •? Active or prior autoimmune disease or history of immunodeficiency
- •? Current or prior use of immunosuppressive agents within 28 days before the first dose of investigational drugs, with the exception of intranasal, inhaled, or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- •? Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GMCSF, M-CSF), thrombopoietin mimetics or erythroid stimulating agents = 2 weeks prior start of study treatment. If erythroid stimulating agents were initiated more than 2 weeks prior to the first dose of study treatment and the patient is on a stable dose, they can be maintained
- •? Experience of solid organ transplant
- •? Evidence of severe or unregulated systemic diseases, such as active hemorrhagic predisposition or active hepatitis B, hepatitis C, and active infections including HIV. However, patients who have suffered or have already been cured of HBV infection (type B hepatitis B central antibody, no anti-HBV DNA) are eligible to participate in this test. Chronic hepatitis B is being treated with anti-viral drugs, and HBV DNA <100IU/ml ramen can be registered. Patients with hepatitis C antibody positive can only participate in the test if the HCV RNA test results are negative.
- •? Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
- •? Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)
- •? Active infection of lung, including pulmonary tuberculosis, pneumonia
- •? Has a history of interstitial lung disease (ILD) or a history of pneumonitis that has required oral or IV steroids.
- •? Pregnant female subject (Female subjects must have a negative urine or serum pregnancy test at screening if of childbearing potential, or be of non-child bearing potential.)
- •? Lactating female subject
- •? Prior malignancy, with the exception of basal cell/ squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 3 years since initiation of that therapy
研究者
相似试验
已完成
不适用
A Phase II clinical trial to evaluate the efficacy and safety of intra-arterial infusion chemotherapy for head and neck squamous cell carcinomahead and neck squamous cell carcinomaJPRN-UMIN000019865Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University40
进行中（未招募）
不适用
Clinical Trial testing the combination of MK-5172 and MK-8742 with Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2, 4, 5 and 6MedDRA version: 16.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 16.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-GBMerck Sharp & Dohme Corp.100
进行中（未招募）
1 期
A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype AFanconi anemia (subtype A)MedDRA version: 20.0Level: LLTClassification code 10055206Term: Fanconi's anemiaSystem Organ Class: 100000004850EUCTR2018-002502-31-ESRocket Pharmaceuticals, Inc.5
进行中（未招募）
1 期
A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype AFanconi anemia (subtype A)MedDRA version: 20.0Level: LLTClassification code 10055206Term: Fanconi's anemiaSystem Organ Class: 100000004850EUCTR2018-002502-31-GBRocket Pharmaceuticals, Inc.5
进行中（未招募）
1 期
Clinical Trial testing the combination of MK-5172 with/without MK-8742 and/or Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2/4/5/6MedDRA version: 17.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.0Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,100